- Home
- VRNT vs DVAX Comparison
VRNT vs DVAX Comparison
Compare VRNT & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNT
- DVAX
- Stock Information
- Founded
- VRNT 1994
- DVAX 1996
- Country
- VRNT United States
- DVAX United States
- Employees
- VRNT N/A
- DVAX N/A
- Industry
- VRNT EDP Services
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- VRNT Technology
- DVAX Health Care
- Exchange
- VRNT Nasdaq
- DVAX Nasdaq
- Market Cap
- VRNT 1.1B
- DVAX 1.3B
- IPO Year
- VRNT N/A
- DVAX 2004
- Fundamental
- Price
- VRNT $21.57
- DVAX $11.29
- Analyst Decision
- VRNT Buy
- DVAX Buy
- Analyst Count
- VRNT 7
- DVAX 4
- Target Price
- VRNT $31.71
- DVAX $26.25
- AVG Volume (30 Days)
- VRNT 2.2M
- DVAX 1.4M
- Earning Date
- VRNT 09-03-2025
- DVAX 08-05-2025
- Dividend Yield
- VRNT N/A
- DVAX N/A
- EPS Growth
- VRNT 79.53
- DVAX N/A
- EPS
- VRNT 0.84
- DVAX N/A
- Revenue
- VRNT $896,006,000.00
- DVAX $294,620,000.00
- Revenue This Year
- VRNT $7.73
- DVAX $21.18
- Revenue Next Year
- VRNT $5.47
- DVAX $16.83
- P/E Ratio
- VRNT $25.75
- DVAX N/A
- Revenue Growth
- VRNT N/A
- DVAX 24.76
- 52 Week Low
- VRNT $14.15
- DVAX $9.22
- 52 Week High
- VRNT $37.31
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- VRNT 58.67
- DVAX 64.07
- Support Level
- VRNT $19.57
- DVAX $11.07
- Resistance Level
- VRNT $22.68
- DVAX $11.48
- Average True Range (ATR)
- VRNT 0.75
- DVAX 0.28
- MACD
- VRNT 0.01
- DVAX 0.07
- Stochastic Oscillator
- VRNT 64.31
- DVAX 82.73
About VRNT Verint Systems Inc.
Verint Systems Inc with its subsidiaries, helps brands provide Boundless customer experience (CX) automation. AI offers a solution, and that's where Verint comes in. It empowers brands with groundbreaking AI via a next-gen open platform. Its Verint Open Platform helps organizations increase CX automation to achieve their strategic objectives and realize ROI. Geographically, it derives a majority of its revenue from the United States.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.